Adipose Inflammation and Diabetes (FAB)

The study investigates whether the addition of resolution molecules can inhibit inflammation and insulin resistance in human tissue taken from obese individuals, and whether the results of these studies correlate with patient-specific resolution phenotypes.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Obese Body Weight Nutrition Disorders Nutritional and Metabolic Diseases Obesity Overnutrition Overweight Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

18 year–60 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Sahlgrenska university hospital

Gothenburg, Västra Götaland County, 40530, Sweden

Location status: Recruiting

Location contact

Emma Borgeson, PhD

CONTACT

+4631342000

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

BMI 30-40 kg/m2
Ptos (i.e. excess skin) > 3 cm
Patient underwent gastric bypass surgery >2 years ago
Patient has had a stable weight ≥6 months at the time of operation
Patient does not smoke (min 6 weeks prior to surgery)

Exclusion criteria

Patients who do not understand spoken and written Swedish
American Society of Anesthesiologists (ASA) classification ≥ 3
Neurological, orthopedic or rheumatologic injury or illness affecting physical ability
Preoperatively known hernia requiring surgical operation
Severe mental illness

Treatment and study plan

Primary outcomes

Inflammatory status

Time frame: 2025

The inflammatory status will be studied in obese patients.

Study contacts

Contact information is provided by the study sponsor or research team.

Christina Biörserud, RN, PhD

CONTACT

[email protected]

+46313420000

Emma Borgeson, PhD

CONTACT

[email protected]

+46313420000

Sponsors and collaborators

Lead sponsor

Göteborg University

Other

Registry information

Official study title

Adipose Tissue Inflammation and Diabetes Development (Fettvävsinflammation Och Diabetesutveckling)

Acronym: FAB

Important dates

Study start: 2019
Primary completion: 2026
Study completion: 2027
First posted: Feb 5, 2020
Registry last updated: May 6, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting